Compare L3Harris Technologies Inc (LHX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Moderna, Inc. — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Moderna, Inc. for 59 Days on average.
| LHX | MRNA | |
|---|---|---|
Market Cap | $44.12B | $78.65B |
Volume | 1,202,852 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $378.48 | $203.46 |
52-Week Low | $233.63 | $22.36 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | $54.56B | $74.80B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.
LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
